Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Zumiez Inc. Announces Fiscal 2025 Second Quarter Results

(NASDAQ:ZUMZ) Second Quarter Comparable Sales Increased 2.5% North American Second Quarter Comparable Sales Increased 4.2% Third Quarter-to-date Comparable Sales up 11.2%

How does Zumiez's North American comparable sales growth compare to its peers in the specialty retail sector? What are the market expectations for ZUMZ's earnings per share after this second quarter results release? How will the reported comparable sales growth affect Zumiez's revenue guidance for FY2025?
Symbol: ZUMZ
Earnings
6 days ago
Read more globenewswire

KBRA Comments on Equity Bancshares, Inc.'s Proposed Acquisition of Frontier Holdings, LLC

(NYSE:EQBK) NEW YORK--(BUSINESS WIRE)-- #creditratingagency--On September 2, 2025, Wichita, KS-based Equity Bancshares, Inc. (NYSE: EQBK) ("Equity” or “the company"), and Omaha, NE-based Frontier H...

What level of accretion or cost‑saving synergies does Equity Bancshares anticipate, and how will those be reflected in its capital ratios and net income guidance post‑integration? What regulatory approvals are required for the merger, what is the expected timeline, and how might those factors impact short‑term stock price volatility? How will the $120 million acquisition and 1.23× price‑to‑book valuation affect EQBK’s earnings per share and return on equity?
Symbol: EQBK
Mergers
6 days ago
Read more businesswire

Phreesia to Acquire AccessOne, Expanding Its Suite of Payment Solutions

(NYSE:PHR) ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) (“Phreesia”), a trusted leader in patient activation, today announced it has entered into a definitive ag...

When is the deal expected to close and what are the key integration milestones that could drive short‑term stock volatility? What revenue and margin expansions can be expected from integrating AccessOne’s payment solutions into Phreesia’s platform? How will the $160 million cash acquisition affect Phreesia’s capital structure and earnings per share?
Symbol: PHR
Mergers
6 days ago
Read more businesswire

BRIXMOR PROPERTY GROUP PRICES OFFERING OF SENIOR NOTES

(NYSE:BRX) NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Brixmor Property Group Inc. (NYSE: BRX) ("Brixmor" or the "Company") announced today that its operating partnership, Brixmor Operating Partnership...

What impact might this financing have on the company's credit rating, cost of capital, and consequently the stock price and yield spreads? How will the $400 million of proceeds be allocated and what effect will this have on Brixmor's leverage ratios and balance sheet strength? What are the key terms of the senior notes (interest rate, maturity, covenants) and how do they compare to current market rates?
Symbol: BRX
Financing
6 days ago
Read more prnewswire

Indaptus Therapeutics Provides Clinical Update

(IDPT) Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases

Will this data point lead to a re‑rating of the stock or trigger any partnership or licensing activity? How does the observed response compare to existing therapies for urothelial cancer and potential market share? What does this partial response mean for the progression of INDPT's Decoy20 program and potential FDA filing timeline?
Symbol: IDPT
Clinical trials
6 days ago
Read more globenewswire

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

(NASDAQ:AMRX) BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval o...

What upside or downside risk does the Q4 2025 product launch present for AMRX’s stock price given potential competition and supply constraints? How much market share can Amneal realistically capture from Janssen’s Risperdal Consta in the next 12‑18 months? What is the expected revenue uplift from the 180‑day CGT exclusivity period and how will it affect AMRX’s valuation?
Symbol: AMRX
Drug approval
6 days ago
Read more globenewswire

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

(NASDAQ:MLYS) RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hyp...

How might the full exercise of the underwriters’ option to purchase additional shares impact the stock’s price and trading volume in the short term? What is the intended allocation of the proceeds and how will it influence upcoming clinical milestones or partnership opportunities? How will the $287.5 million capital raise affect Mineralys’ cash runway and dilution?
Symbol: MLYS
Capital
6 days ago
Read more globenewswire